Novartis acquires AveXis, including the AVXS-101 treatment for SMA Pfizer and Allogene to collaborate on developing donor-derived CAR T-cell therapies Orchard Therapeutics acquires GSK rare disease gene therapy portfolio Pfizer launching phase 1b trial of gene therapy for Duchenne muscular dystrophy Personalised cancer vaccine directs T-cell response to ovarian cancer Goldman Sachs report highlights need for gene therapy pricing strategy Clinical trial shows gene therapy for beta-thalassemia is safe and effective Trial of CRISPR to treat beta-thalassemia to start in Europe GE launching prefabricated manufacturing units for producing virus-based gene and cell therapies
Non-viral genetic therapy strategies for the treatment of ataxia telangiectasia
James Grey received the ESGCT-sponsored prize for best poster presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about his winning presentation here!
Gene therapy for thrombotic thrombocytopaenic purpura
Robyn Bell received the ESGCT-sponsored prize for best oral presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about her winning presentation here!
CRISPR-Cas9 genome editing - molecular scissors a bit too sharp?
Grégoire Cullot received the ESGCT-sponsored prize for best oral presentation at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about his winning presentation here!
Dgkk as a new therapeutic target in the Fmr1-KO murine model of Fragile X
Karima Habbas received the ESGCT-sponsored prize for best poster at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about her winning presentation here!